Oncology
🇺🇸 FDA Page 11FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 121–132 of 246 articles
NCCN Adds Nuvation Bio's Taletrectinib (IBTROZI) to Cancer Treatment Guidelines for ROS1-Positive NSCLC with Brain Metastases
Bispecific Antibodies in Hematological Malignancies: Teclistamab & Market Trends 2025
Pembrolizumab FDA Approval: Expanded Use for MSI-High Solid Tumors
4th Annual COG 2026: No Major Pharma News Today
Cancer Drug Supply Chain Security in Africa: Anti-Counterfeiting & Distribution Controls
AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Bispecific Antibody Therapies in B-Cell Lymphomas: FDA Approvals & Market Outlook
Pembrolizumab KEYNOTE-826 Trial: Expanded Use in Advanced Cervical Cancer
FDA Accelerated Approval Oncology 2026: Market Analysis & Future Trends
Ensartinib Phase 3 Results: Market Impact in ALK-Positive NSCLC US
Pembrolizumab Label Expansion: KEYNOTE-826 Trial Insights on Advanced Cervical Cancer
FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib